Oral cancer chemoprevention: COX-2 inhibitor a covenant
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20211043Keywords:
COX-2 inhibitor, Inflammation, Oral cancerAbstract
Oral cancer survival remains poor despite advancement in treatment modalities. In oral cancer and oral premalignant lesions, cyclooxygenase-2 (COX-2) is widely expressed and tends to be enhanced especially in high-risk oral lesions. Numerous researches suggests that the inflammation pathway of cyclooxygenase/prostaglandin E2 (PGE2) leads to the development and progression of a number of cancers, including oral squamous cell carcinoma (OSCC). With an emphasis on research data, this article discusses the relationship between inflammation and cancer, summarizes the use of anti-inflammatory agents COX-2 inhibitors for cancer chemoprevention and treatment, and explains the mechanisms underlying the anti-cancer effects of anti-inflammatory agents (COX-2 inhibitors).
Metrics
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Global facts on tobacco or oral health. World Health Organization, Geneva, 2018. Available at: http://www.who.int/oral_health/publications/fact_sheet_tobacco/en/index1.html. Accessed on 22nd October, 2020.
Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. Histological Typing of Cancer and Pre-cancer of the Oral Mucosa, Ed. 2, Berlin, Germany: Springer-Verlag. 1997;21-6.
Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst. 1998;90(20):1529-36.
Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998;90(21):1609-20.
Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med. 2000;342(26):1960-8.
Hawkey CJ. COX-2 inhibitor. Lancet. 1999;353(9149):307-14.
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946-52.
Goldstein JL, Silverstein FE, Agrawal NM. Reduced risk of upper gastrointestinal ulcer complications with Celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. 2000;95(7):1681-90.
Noble SC, King DS, Olutade JI. Cyclooxygenase-2 enzyme inhibitors: place in therapy. Am Fam Physician. 2000;61(12):3669-76.
Nikitakis NG, Hebert C, Lopes MA, Reynolds MA, Sauk JJ. PPA Rgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer. 2002;98(6):817-23.
Jackel EC, Raja S, Tan J, Das SK, Dey SK, Griod DA et al. Correlation of expression of cycloozygenase-2, vascular endothelial growth factor, peroxisome proliferators-activated receptor (delta) with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127(10):1253-59.
Kawamori T, Rao CV, Seihbert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58(3):409-12.
Masterrer JL, Leahy KM, Koki AT, Zweifel BS. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60(5):1306-11.
Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173-96.
Munn LL. Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med. 2017;9(2):e1370.
Bonavita E, Galdiero MR, Jaillon S, Mantovani A. Phagocytes as corrupted policemen in cancer-related inflammation. Adv Cancer Res. 2015;128:141-71.
Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.
Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci USA. 2012;109(38):15101-8.
Hasselbalch HC. Smoking as a contributing factor for development of polycythemia vera and related neoplasms. Leuk Res. 2015;39(11):1137-45.
Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: Short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425-30.
Erovic BM, Pelzmann M, Turhani D, Pammer J, Niederberger V, Neuchrist C et al. Differential expression pattern of cyclooxygenase-1 and -2 in head and neck squamous cell carcinoma. Acta Otolaryngol. 2003;123(8):950-3.
Pontes HA, Pontes FS, Fonseca FP, de Carvalho PL, Pereira EM, de Abreu MC et al. Nuclear factor kappa B and cyclooxygenase-2 immunoexpression in oral dysplasia and oral squamous cell carcinoma. Ann Diagn Pathol. 2013;17(1):45-50.
Shibata M, Kodani I, Osaki M, Araki K, Adachi H, Ryoke K. Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol. 2005;41(3):304-12.
Seyedmajidi M, Shafaee S, Siadati S, Khorasani M, Bijani A, Ghasemi N. Cyclo-oxygenase-2 expression in oral squamous cell carcinoma. J Cancer Res Ther. 2014;10(4):1024-9.
Abrahao AC, Castilho RM, Squarize CH, Molinolo AA, dos Santos-Pinto DJ, Gutkind JS. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol. 2010;46(12):880-7.
Yang SF, Chen MK, Hsieh YS, Chung TT, Hsieh YH, Lin CW, et al. Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells. J Biol Chem. 2010;285(39):29808-16.
Byatnal AA, Byatnal A, Sen S, Guddattu V, Solomon MC. Cyclooxygenase-2-An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma-An Immunohistochemical Study. Pathol Oncol Res. 2015;21(4):1123-31.
Pannone G, Sanguedolce F, De Maria S, Farina E, Lo Muzio L, Serpico R et al. Cyclooxygenase isozymes in oral squamous cell carcinoma: A real-time RT-PCR study with clinicopathological correlations. Int J Immunopathol Pharmacol. 2007;20(2):317-24.
Qian M, Qian D, Jing H, Li Y, Ma C, Zhou Y. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Oncol Rep. 2014;32(4):1681-8.
Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcin. 1999;25(4):231-40.
Harris RE, Alshafie GA, Abou-Issa H. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000;60(8):2101-03.
Grabbs CJ, Lubet RA, Koki AT. Celecoxib inhibits N-Butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 2000;60(20):5599-602.
Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP et al. Cyclooxygenase-2 expression up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(5):9991-4.
Marnett LJ. Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev. 1994;13(3-4):303-8.
Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83(3):705-16.
Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000;7(11):1163-70.
Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaranmaiah K. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract (review). Ann N Y Acad Sci. 2001;952:109-15.
Yamamoto K, Kitayama W, Denda A, Morisaki A, Kuniyasu H, Kirita T. Inhibitory effects of selective cyclooxygenase-2 inhibitors, nimesulide and etodolac, on the development of squamous cell dysplasias and carcinomas of the tongue in rats initiated with 4-nitroquinoline 1-oxide. Cancer Lett. 2003;199(2):121-9.
Yoshida K, Tanaka T, Kohno H, Sakata K, Kawamori T, Mori H et al. A COX-2 inhibitor, nimesulide, inhibits chemically-induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression. Histol Histopathol. 2003;18(1):39-48.
Minter HA, Evesion JW, Huntley S, Elder DJ, Hague A. The cyclooxygenase-2 selective inhibitor NS398 inhibits proliferation of oral carcinoma cells lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res. 2003;9(5):1885-97.
Tanaka T, Nishikawa A, Mori Y, Morishita Y, Mori H. Inhibitory effects of non-steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. Cancer Lett. 1989;48(3):177-82.
Tsujii M, DuBois RN. Alteration in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell. 1995;83(3):493-501.
Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Investig. 1995;96(1):491-503.
Jaeckel EC, Raja S, Tan J, Das SK, Dey SK, Girod DA et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferators-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol. Head Neck Surg. 2001;127(10):1253-9.
Gallo O, Franchi A, Magnelli L, Sardi L, Boddi V, Chiarugi V et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer: implications for angiogenesis and metastasis. Neoplasia. 2001;3(1):53-61.
Chen YJ, Jin YT, Shieh DB, Tsai ST, Wu L. W. Molecular characterization of angiogenic properties of human oral squamous cell carcinoma cells. Oral Oncol. 2002;38(7):699-702.
Tsujii M, Kawano S, Tsujii S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cells. 1998; 93(5):705-15.
Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada L, Kitayama J et al. Inhibition of hematogenous metastasis of colon cancer in mice by a selective Cox-2 inhibitor, JTE522. Br J Cancer. 1999;81(8):1274-9.
Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cells. Laryngoscope. 2002;112(5):839-43.
Soh JW, Weinstein IB. Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog Exp Tumor Res. 2003;37:261-85.
